The Romanian version of the Geriatric Depression Scale: Reliability and validity

Ștefan, Adina Maria; Băban, Adriana

doi:10.24193/cbb.2017.21.10

Cited by 8 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, similar to the results of the correlation of the items in the GDS-15 with measures of life satisfaction, quality of life, activities of daily living, and suicidal ideation (Friedman et al, 2005;Imai et al, 2014;Lucas-Carrasco, 2012;Ștefan & Băban, 2017), in this study a significant negative correlation was found between the items of the GDS-15, and a subjective well-being scale and a quality of life questionnaire. This is evidence of divergent validity based on external criteria according to the theory.…”

Section: Discussionsupporting

confidence: 88%

“…In the GDS-15, Ștefan and Băban (2017) found evidence of internal consistency, temporal stability, divergent validity with life satisfaction, and criterion validity when discriminating between depressed and nondepressed in Romanian older adults. Similarly, Dow et al (2018) found evidence of internal consistency and convergent validity with other measures of depression in immigrant Chinese in Australia.…”

Section: Introductionmentioning

confidence: 96%

“…Both versions do not include items on the somatic symptoms of depression and are one-dimensional. They present a dichotomous response format (Yes/No) that makes them easy to administer, where conventionally in the GDS-15, a number equal to or greater than five positive items assumes mild depression and a number equal to or greater than 10 positive items assumes moderate to severe depression, and hence follow-up through clinical evaluation is recommended to confirm the diagnosis (Ștefan & Băban, 2017).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Geriatric Depression Scale (GDS-15): Validation in Mexico and Disorder in the State of Knowledge

Quiroz

Flores

Castro

2020

Int J Aging Hum Dev

View full text Add to dashboard Cite

The objective of this study was to evaluate the reliability and validity of the Geriatric Depression Scale in its 15-item version (GDS-15) in Mexican older adults. Participants included 1178 older adults between the ages of 60 and 94 ( M = 69.16, SD = 7.69); 53.9% were women and 55.8% were married or with a partner. They completed the GDS-15, a subjective well-being scale, and a quality-of-life questionnaire. A Kuder–Richardson coefficient of .80 was obtained, which indicates an acceptable internal consistency of the GDS-15, as well as evidence of divergent validity with significant correlations of −.783 with subjective well-being and −.569 with quality of life, in addition to concurrent validity when discriminating between participants with low scores from those with high scores of depressive symptoms. The need for a simple screening tool such as the GDS-15 that helps in the identification of depressive symptoms in Mexican older adults is underlined.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Introductionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Geriatric Depression Scale (GDS-15): Validation in Mexico and Disorder in the State of Knowledge

Quiroz

Flores

Castro

2020

Int J Aging Hum Dev

View full text Add to dashboard Cite

show abstract

“…The authors recommend applying the scale to elderly patients with dementia or other physical impairment, which could speed up the fatigue process. This scale was adapted for the Romanian population in 2017 (13). The difference is that the population the authors evaluated was the normal elderly population, while this study refers to the clinical population.…”

Section: Methodsmentioning

confidence: 99%

“…At the same time, the GDS-SF with the PAD were entirely correlated, thus with a global distress score, and then with the subscale of the dysfunctional emotions on the depressive dimension, that is the exact concept validated by the study. The criterion validity of the scale was deduced in the initial adaptation on the Romanian population that did not suffer from cognitive impairment by dividing the patients into 2 groups -one whose subjects met the conditions necessary for diagnosis with major depressive episode according to DSM IV-TR criteria and the other one that was the control group (13). The GDS-SF averages were then compared using the simple t-test.…”

Section: Instrumentsmentioning

confidence: 99%

Distress in neurocognitive disorders due to Alzheimer's disease and stroke

et al. 2020

View full text Add to dashboard Cite

Patients with neurocognitive disorders experience subjectively the concept of quality of life; this is the reason why researchers avoid approaching this concept and prefer to focus attention on the emotional profile of the caregivers. Many studies highlight the efforts both emotional and financial made by caregivers in case of patients diagnosed with neurocognitive disorders. The present study shows the differences between the patients diagnosed with neurocognitive disorder due to Alzheimer's disease and patients diagnosed with stroke, as well as the Romanian norms for the short form of Geriatric Depression Scale. The study group consisted of the clinical population (N=45), selected according to the inclusion/exclusion criteria, following the principles of Helsinki Declaration for Ethical Medical Research.

show abstract

Depression and Suicide Risk Screening

O’Connor

Perdue

Coppola

et al. 2023

JAMA

View full text Add to dashboard Cite

ImportanceDepression is common and associated with substantial burden. Suicide rates have increased over the past decade, and both suicide attempts and deaths have devastating effects on individuals and families.ObjectiveTo review the benefits and harms of screening and treatment for depression and suicide risk and the accuracy of instruments to detect these conditions among primary care patients.Data SourcesMEDLINE, PsychINFO, Cochrane library through September 7, 2022; references of existing reviews; ongoing surveillance for relevant literature through November 25, 2022.Study SelectionEnglish-language studies of screening or treatment compared with control conditions, or test accuracy of screening instruments (for depression, instruments were selected a priori; for suicide risk, all were included). Existing systematic reviews were used for treatment and test accuracy for depression.Data Extraction and SynthesisOne investigator abstracted data; a second checked accuracy. Two investigators independently rated study quality. Findings were synthesized qualitatively, including reporting of meta-analysis results from existing systematic reviews; meta-analyses were conducted on original research when evidence was sufficient.Main Outcomes and MeasuresDepression outcomes; suicidal ideation, attempts, and deaths; sensitivity and specificity of screening tools.ResultsFor depression, 105 studies were included: 32 original studies (N=385 607) and 73 systematic reviews (including ≈2138 studies [N ≈ 9.8 million]). Depression screening interventions, many of which included additional components beyond screening, were associated with a lower prevalence of depression or clinically important depressive symptomatology after 6 to 12 months (pooled odds ratio, 0.60 [95% CI, 0.50-0.73]; reported in 8 randomized clinical trials [n=10 244]; I2 = 0%). Several instruments demonstrated adequate test accuracy (eg, for the 9-item Patient Health Questionnaire at a cutoff of 10 or greater, the pooled sensitivity was 0.85 [95% CI, 0.79-0.89] and specificity was 0.85 [95% CI, 0.82-0.88]; reported in 47 studies [n = 11 234]). A large body of evidence supported benefits of psychological and pharmacologic treatment of depression. A pooled estimate from trials used for US Food and Drug Administration approval suggested a very small increase in the absolute risk of a suicide attempt with second-generation antidepressants (odds ratio, 1.53 [95% CI, 1.09-2.15]; n = 40 857; 0.7% of antidepressant users had a suicide attempt vs 0.3% of placebo users; median follow-up, 8 weeks). Twenty-seven studies (n = 24 826) addressed suicide risk. One randomized clinical trial (n=443) of a suicide risk screening intervention found no difference in suicidal ideation after 2 weeks between primary care patients who were and were not screened for suicide risk. Three studies of suicide risk test accuracy were included; none included replication of any instrument. The included suicide prevention studies generally did not demonstrate an improvement over usual care, which typically included specialty mental health treatment.Conclusions and RelevanceEvidence supported depression screening in primary care settings, including during pregnancy and postpartum. There are numerous important gaps in the evidence for suicide risk screening in primary care settings.

show abstract

The Romanian version of the Geriatric Depression Scale: Reliability and validity

Cited by 8 publications

References 0 publications

The Geriatric Depression Scale (GDS-15): Validation in Mexico and Disorder in the State of Knowledge

The Geriatric Depression Scale (GDS-15): Validation in Mexico and Disorder in the State of Knowledge

Distress in neurocognitive disorders due to Alzheimer's disease and stroke

Depression and Suicide Risk Screening

Contact Info

Product

Resources

About